Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST ASTHMA-2
jRCT2031260574Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of felcorekibart in asthma (2 arms), sponsored by GSK. Primary endpoint: Annualized rate of clinically significant asthma exacerbations. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
felcorekibart
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031260574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260574.